1. Home
  2. AMPH vs URGN Comparison

AMPH vs URGN Comparison

Compare AMPH & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$18.72

Market Cap

971.8M

Sector

Health Care

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$27.99

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPH
URGN
Founded
1996
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
971.8M
1.4B
IPO Year
2005
2016

Fundamental Metrics

Financial Performance
Metric
AMPH
URGN
Price
$18.72
$27.99
Analyst Decision
Buy
Strong Buy
Analyst Count
8
7
Target Price
$28.38
$29.29
AVG Volume (30 Days)
710.6K
816.1K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$719,887,000.00
$1,128,000.00
Revenue This Year
$6.90
$129.09
Revenue Next Year
$4.64
$70.96
P/E Ratio
$137.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.65
$4.36
52 Week High
$31.26
$32.37

Technical Indicators

Market Signals
Indicator
AMPH
URGN
Relative Strength Index (RSI) 44.87 54.22
Support Level $16.84 $27.34
Resistance Level $20.08 $30.00
Average True Range (ATR) 0.80 1.64
MACD 0.11 -0.34
Stochastic Oscillator 73.53 14.12

Price Performance

Historical Comparison
AMPH
URGN

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: